Offerings
|
Aug. 08, 2024
USD ($)
shares
|
Offering: 1 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued under the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan (the "2016 Plan")
|
Amount Registered | shares |
2,000,000
|
Proposed Maximum Offering Price per Unit |
14.42
|
Maximum Aggregate Offering Price |
$ 28,840,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 4,256.78
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Estimated solely for calculating the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 the Act, on the basis of the average of the high and low sale prices of the shares of Common Stock of the Registrant on The Nasdaq Capital Market on August 5, 2024, within five business days prior to filing .
|
Offering: 2 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on February 12, 2024
|
Amount Registered | shares |
290,000
|
Proposed Maximum Offering Price per Unit |
19.68
|
Maximum Aggregate Offering Price |
$ 5,707,200
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 842.38
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 3 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on March 1, 2024
|
Amount Registered | shares |
31,000
|
Proposed Maximum Offering Price per Unit |
19.89
|
Maximum Aggregate Offering Price |
$ 616,590
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 91.01
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 4 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on March 1, 2024
|
Amount Registered | shares |
31,000
|
Proposed Maximum Offering Price per Unit |
19.89
|
Maximum Aggregate Offering Price |
$ 616,590
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 91.01
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 5 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on April 1, 2024
|
Amount Registered | shares |
31,000
|
Proposed Maximum Offering Price per Unit |
17.26
|
Maximum Aggregate Offering Price |
$ 535,060
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 78.97
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 6 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on April 1, 2024
|
Amount Registered | shares |
31,000
|
Proposed Maximum Offering Price per Unit |
17.26
|
Maximum Aggregate Offering Price |
$ 535,060
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 78.97
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 7 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on April 1, 2024
|
Amount Registered | shares |
40,000
|
Proposed Maximum Offering Price per Unit |
17.26
|
Maximum Aggregate Offering Price |
$ 690,400
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 101.9
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 8 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
200,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 2,762,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 407.67
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 9 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
31,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 428,110
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 63.19
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 10 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
200,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 2,762,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 407.67
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 11 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
40,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 552,400
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 81.53
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 12 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
40,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 552,400
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 81.53
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 13 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on May 1, 2024
|
Amount Registered | shares |
40,000
|
Proposed Maximum Offering Price per Unit |
13.81
|
Maximum Aggregate Offering Price |
$ 552,400
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 81.53
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 14 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on June 3, 2024
|
Amount Registered | shares |
200,000
|
Proposed Maximum Offering Price per Unit |
12
|
Maximum Aggregate Offering Price |
$ 2,400,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 354.24
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 15 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on June 3, 2024
|
Amount Registered | shares |
250,000
|
Proposed Maximum Offering Price per Unit |
12
|
Maximum Aggregate Offering Price |
$ 3,000,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 442.8
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 16 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
40,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 528,400
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 77.99
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 17 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
6,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 79,260
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 11.7
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 18 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
10,500
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 138,705
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 20.47
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 19 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
10,500
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 138,705
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 20.47
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 20 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
10,500
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 138,705
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 20.47
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 21 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
175,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 2,311,750
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 341.21
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 22 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
46,500
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 614,265
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 90.67
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 23 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
24,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 317,040
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 46.8
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 24 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
15,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 198,150
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 29.25
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 25 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on July 1, 2024
|
Amount Registered | shares |
200,000
|
Proposed Maximum Offering Price per Unit |
13.21
|
Maximum Aggregate Offering Price |
$ 2,642,000
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 389.96
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 26 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on August 1, 2024
|
Amount Registered | shares |
12,000
|
Proposed Maximum Offering Price per Unit |
16.28
|
Maximum Aggregate Offering Price |
$ 195,360
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 28.84
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|
Offering: 27 |
|
Offering: |
|
Fee Previously Paid |
false
|
Other Rule |
true
|
Security Type |
Equity
|
Security Class Title |
Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on August 1, 2024
|
Amount Registered | shares |
7,500
|
Proposed Maximum Offering Price per Unit |
16.28
|
Maximum Aggregate Offering Price |
$ 122,100
|
Fee Rate |
0.01476%
|
Amount of Registration Fee |
$ 18.02
|
Offering Note |
Represents 2,000,000 shares of common stock, par value $0.01 per share (“Common Stock”) of Viridian Therapeutics, Inc. (the “Registrant”) issuable pursuant to the Registrant’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”), 290,000 shares of Common Stock of the Registrant issuable pursuant to a Stock Option Inducement Award granted on February 12, 2024, 62,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on March 1, 2024, 102,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on April 1, 2024, 551,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on May 1, 2024, 450,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on June 3, 2024, 538,000 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on July 1, 2024, and 19,500 shares of Common Stock of the Registrant issuable pursuant to the Stock Option Inducement Awards granted on August 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8, also includes additional shares of Common Stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 Plan and each of the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. Based on the exercise price on the date of grant.
|